0000000001097804

AUTHOR

Marianna Storto

showing 2 related works from this author

Expression of metabotropic glutamate receptors in murine thymocytes and thymic stromal cells

2000

RT-PCR combined with immunoblotting showed the expression of group-I (mGlu1 and 5) and group-II (mGlu2 and 3) metabotropic glutamate receptors in whole mouse thymus, isolated thymocytes and TC-1S thymic stromal cell line. Cytofluorimetric analysis showed that mGlu-5 receptors were absent in CD4(-)/CD8(-) but present in more mature CD4(+) CD8(+) and CD4(+)CD8(-) thymocytes. mGlu-1a receptors showed an opposite pattern of expression with respect to mGlu5, whereas mGlu2/3 receptor expression did not differ between double negative and double positive cells. mGlu receptors expressed in both thymic cell components were functional, as indicated by measurements of polyphosphoinositide hydrolysis or…

CD4-Positive T-LymphocytesMalemedicine.medical_specialtyStromal cellNeuroimmunomodulationReceptor expressionBlotting WesternImmunologyGene ExpressionThymus GlandCD8-Positive T-LymphocytesReceptors Metabotropic GlutamateCell LineMicePhosphatidylinositol PhosphatesInternal medicineCyclic AMPmedicineAnimalsImmunology and AllergyCycloleucineRNA MessengerReceptorReverse Transcriptase Polymerase Chain ReactionChemistryMetabotropic glutamate receptor 5HydrolysisMetabotropic glutamate receptor 6Flow CytometryCell biologyMice Inbred C57BLNeuroprotective AgentsEndocrinologyMetabotropic receptormetabotropic glutamate receptors; tc-1s cells; thymocytesNeurologyMetabotropic glutamate receptorMetabotropic glutamate receptor 1Neurology (clinical)Stromal CellsSignal TransductionJournal of Neuroimmunology
researchProduct

Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons

2009

Metabotropic glutamate (mGlu) receptors have been considered potential targets for the therapy of experimental parkinsonism. One hypothetical advantage associated with the use of mGlu receptor ligands is the lack of the adverse effects typically induced by ionotropic glutamate receptor antagonists, such as sedation, ataxia, and severe learning impairment. Low doses of the mGlu2/3 metabotropic glutamate receptor agonist, LY379268 (0.25-3 mg/kg, i.p.) increased glial cell line-derived neurotrophic factor (GDNF) mRNA and protein levels in the mouse brain, as assessed by in situ hybridization, real-time PCR, immunoblotting, and immunohistochemistry. This increase was prominent in the striatum, …

medicine.medical_specialtymedicine.drug_classlcsh:MedicineSubstantia nigraReceptors Metabotropic GlutamateSettore BIO/09 - FisiologiaPolymerase Chain ReactionMiceNeurotrophic factorsInternal medicinemedicineGlial cell line-derived neurotrophic factorAnimalsGlial Cell Line-Derived Neurotrophic FactorRNA MessengerAmino Acidslcsh:ScienceReceptorIn Situ HybridizationNeurological Disorders/Movement DisordersNeuronsMultidisciplinarybiologyNeuroscience/Neuronal and Glial Cell Biologylcsh:RGlutamate receptorBridged Bicyclo Compounds HeterocyclicReceptor antagonistCorpus StriatumEndocrinologyMetabotropic receptornervous systemMetabotropic glutamate receptorSettore BIO/14 - Farmacologiabiology.proteinlcsh:QNeuroscience/Neurobiology of Disease and RegenerationReceptors Metabotropic Glutamate/agonists Glial Cell Line-Derived Neurotrophic FactorResearch Article
researchProduct